Linrodostat mesylate
Based on 7 publication(s) in Google Scholar
Linrodostat (BMS-986205) mesylate is a selective irreversible inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), which effectively inhibits IDO1-HEK293 mesylate cells with an IC50 value of 1.1 nM. Linrodostat mesylate demonstrates good pharmacological activity in advanced cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2221034-29-1
- Formule: C25H28ClFN2O4S
- Masse moléculaire:507.02
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Linrodostat mesylate
More- Immunity. 2021 Oct 12;54(10):2354-2371.e8. [Abstract]
- Cell Death Differ. 2021 Feb;28(2):715-729. [Abstract]
- MedComm (2020). 2026 Mar 30;7(4):e70709. [Abstract]
- J Neuroinflammation. 2024 Nov 28;21(1):307. [Abstract]
- Cell Rep. 2024 Sep 13;43(9):114741. [Abstract]
- Heidelberg University. 2025.
- SSRN. 2023 Dec 1.
Activité biologique
|
IDO1 1.1 nM (IC50) |
Chemical Information
-
CAS No. 2221034-29-1
-
Masse moléculaire 507.02
-
Formule C25H28ClFN2O4S
-
SMILES
O=C(NC1=CC=C(Cl)C=C1)[C@H](C)[C@@](CC2)([H])CC[C@H]2C3=CC=NC4=C3C=C(F)C=C4.OS(C)(=O)=O
-
Synonyms
BMS-986205 mesylate; ONO-7701 mesylate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Immunity
Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity. [Abstract]2021 Oct 12;54(10):2354-2371.e8. PMID: 34614413 -
Cell Death Differ
Exosome-derived miR-142-5p remodels lymphatic vessels and induces IDO to promote immune privilege in the tumour microenvironment. [Abstract]2021 Feb;28(2):715-729. PMID: 32929219 -
MedComm (2020)
Metabolic Alterations in Macrophage Subtypes Propel Immune and Stromal Remodeling in Neurofibroma's Malignant Progression. [Abstract]2026 Mar 30;7(4):e70709. PMID: 41930352 -
J Neuroinflammation
Taprenepag restores maternal-fetal interface homeostasis for the treatment of neurodevelopmental disorders. [Abstract]2024 Nov 28;21(1):307. PMID: 39609821 -
Cell Rep
Integrated metabolic-transcriptomic network identifies immunometabolic modulations in human macrophages. [Abstract]2024 Sep 13;43(9):114741. PMID: 39276347 -
-
Pureté et documentation
Références
[1]. Richards T, et al. Cell based functional assays for IDO1 inhibitor screening and characterization. Oncotarget. 2018 Jul 20;9(56):30814-30820. [Content Brief]
[2]. Lillian L. Siu, et al. Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. AACR; Cancer Res. 2017; 77 (13 Suppl): Abstract nr CT116. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Linrodostat mesylate Related Classifications
HY-101560A Related Classifications
Powered by Bioz